frontline treatment with
DARZALEX FASPRO® and DARZALEX®
Learn more about DARZALEX FASPRO® or DARZALEX®
- The PERSEUS Trial: DARZALEX FASPRO® + VRd for transplant-eligible patients with newly diagnosed multiple myeloma
- The MAIA Trial: DARZALEX FASPRO® or DARZALEX® + Rd for transplant-ineligible patients with newly diagnosed multiple myeloma
Explore key data in the treatment of newly diagnosed multiple myeloma from the pivotal PERSEUS and MAIA trials:
In the treatment of transplant-eligible patients with newly diagnosed multiple myeloma, educate your patients about DARZALEX FASPRO® + VRd, a treatment for induction and consolidation that may help them experience deep responses.2
Discover the Data
In the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma, you can help your patients learn about treating until disease progression or unacceptable toxicity with DARZALEX® + Rd.1
Explore the DataDARZALEX FASPRO® and DARZALEX® offer established efficacy and safety
You play a crucial role in educating your patients about an effective treatment. DARZALEX FASPRO®- and DARZALEX®-based regimens are becoming standards of care for you and your patients.
Understand our legacy as the #1 prescribed monoclonal antibody for newly diagnosed multiple myeloma3*
*According to IQVIA claims data.2015: IV approval
DARZALEX® as an intravenous infusion gained FDA approval as the first-in-class anti-CD38 monoclonal antibody to treat newly diagnosed multiple myeloma.1
2019: MAIA FDA approval
The DARZALEX® + Rd triplet regimen is FDA approved as a frontline treatment for newly diagnosed, transplant-ineligible patients.1
2020: DARZALEX FASPRO® approval
DARZALEX FASPRO® was approved in 2020 as the first and only monoclonal antibody subcutaneous injection. DARZALEX FASPRO® has an administration time of ~3-5 minutes.2†
DARZALEX FASPRO® offers a daratumumab-based option with faster administration and fewer systemic ARRs than DARZALEX®.2
2024: PERSEUS FDA approval
The DARZALEX FASPRO® + VRd quad regimen gained FDA approval for transplant-eligible patients with newly diagnosed multiple myeloma based on the PERSEUS trial’s primary endpoint of progression-free survival.2
TODAY
>682,000 patients have been treated worldwide with daratumumab across all indications of DARZALEX FASPRO® and DARZALEX®.4‡
2015: IV approval
DARZALEX® as an intravenous infusion gained FDA approval as the first-in-class anti-CD38 monoclonal antibody to treat newly diagnosed multiple myeloma.1
2019: MAIA FDA approval
The DARZALEX® + Rd triplet regimen is FDA approved as a frontline treatment for newly diagnosed, transplant-ineligible patients.1
2020: DARZALEX FASPRO® approval
DARZALEX FASPRO® was approved in 2020 as the first and only monoclonal antibody subcutaneous injection. DARZALEX FASPRO® has an administration time of ~3-5 minutes.2†
DARZALEX FASPRO® offers a daratumumab-based option with faster administration and fewer systemic ARRs than DARZALEX®.2
2024: PERSEUS FDA approval
The DARZALEX FASPRO® + VRd quad regimen gained FDA approval for transplant-eligible patients with newly diagnosed multiple myeloma based on the PERSEUS trial’s primary endpoint of progression-free survival.2
TODAY
>682,000 patients have been treated worldwide with daratumumab across all indications of DARZALEX FASPRO® and DARZALEX®.4‡
ARRs=administration-related reactions; DVRd=DARZALEX FASPRO® (D) + bortezomib (V) + lenalidomide (R) + dexamethasone (d); FDA=U.S. Food and Drug Administration; IV=intravenous; Rd=lenalidomide (R) + dexamethasone (d); VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).
†~3-5 minutes refers to the time it takes to administer DARZALEX FASPRO®. It does not account for all aspects of treatment.2
‡Across all indications for DARZALEX FASPRO® and DARZALEX®. As of June 30, 2025. Estimate based on projected patients, calculations of demand, use in clinical trials, and duration of treatment.4
References:
- DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- Data on file. RF-481588. Janssen Biotech, Inc.
- Johnson & Johnson. Press release. DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma. Published November 6, 2025. Accessed November 25, 2025. https://www.jnj.com/media-center/press-releases/darzalex-faspro-is-the-first-and-only-treatment-approved-by-the-u-s-fda-for-patients-with-high-risk-smoldering-multiple-myeloma
- Data on file. RF-482194. Janssen Biotech, Inc.
